ALX Oncology Holdings Inc.
ALXO
Price:
$2.18
Market Cap:
$114.82M
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers way...[Read more]
Industry
Biotechnology
IPO Date
2020-07-17
Stock Exchange
NASDAQ
Ticker
ALXO
The ROE as of September 2024 (TTM) for ALX Oncology Holdings Inc. (ALXO) is -946.88%
According to ALX Oncology Holdings Inc.’s latest financial reports and current stock price. The company's current ROE is -946.88%. This represents a change of 6.34% compared to the average of -14.70% of the last 4 quarters.
ALX Oncology Holdings Inc. (ALXO) Historical ROE (quarterly & annually)
How has ALXO ROE performed in the past?
The mean historical ROE of ALX Oncology Holdings Inc. over the last ten years is 1.14%. The current -946.88% ROE has changed -182.88% with respect to the historical average. Over the past ten years (40 quarters), ALXO's ROE was at its highest in in the December 2019 quarter at 2.81%. The ROE was at its lowest in in the March 2019 quarter at -46.29%.
Average
1.14%
Median
38.27%
Minimum
-149.98%
Maximum
6.97%
ALX Oncology Holdings Inc. (ALXO) ROE by Quarter and Year
Discovering the peaks and valleys of ALX Oncology Holdings Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 7.07%
Maximum Annual ROE = 6.97%
Minimum Annual Increase = -4748.58%
Minimum Annual ROE = -149.98%
| Year | ROE | Change |
|---|---|---|
| 2023 | -84.76% | -323.41% |
| 2022 | 37.94% | -8.18% |
| 2021 | 41.32% | 7.07% |
| 2020 | 38.59% | -99.45% |
| 2019 | 6.97% | -4748.58% |
ALX Oncology Holdings Inc. (ALXO) Average ROE
How has ALXO ROE performed in the past?
The current ROE of ALX Oncology Holdings Inc. (ALXO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.83%
5-year avg
1.40%
10-year avg
1.14%
ALX Oncology Holdings Inc. (ALXO) ROE vs. Peers
How is ALXO’s ROE compared to its peers?
ALX Oncology Holdings Inc.’s ROE is greater than Cabaletta Bio, Inc. (-43.98%), greater than Viracta Therapeutics, Inc. (-292.12%), greater than EyePoint Pharmaceuticals, Inc. (-43.24%), greater than Biomea Fusion, Inc. (-91.86%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Immatics N.V. (-23.40%), greater than BioAtla, Inc. (-169.69%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Dyne Therapeutics, Inc. (-68.85%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Century Therapeutics, Inc. (-65.37%), greater than C4 Therapeutics, Inc. (-44.60%), greater than TCR2 Therapeutics Inc. (-89.51%), greater than Revolution Medicines, Inc. (-34.57%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Atreca, Inc. (-195.22%), greater than Passage Bio, Inc. (-70.73%),
| Company | ROE | Market cap |
|---|---|---|
| -43.98% | $192.46M | |
| -292.12% | $9.07M | |
| -43.24% | $473.10M | |
| -91.86% | $288.96M | |
| -62.63% | $4.32B | |
| -23.40% | $1.31B | |
| -169.69% | $81.20M | |
| -83.65% | $55.14M | |
| -68.85% | $3.45B | |
| -28.01% | $1.58B | |
| -28.37% | $981.54M | |
| -57.89% | $774.98M | |
| -42.61% | $576.83M | |
| -65.37% | $134.70M | |
| -44.60% | $440.99M | |
| -89.51% | $58.11M | |
| -34.57% | $7.44B | |
| -69.08% | $306.26M | |
| -195.22% | $3.57M | |
| -70.73% | $45.12M |
Build a custom stock screener for ALX Oncology Holdings Inc. (ALXO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALX Oncology Holdings Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ALX Oncology Holdings Inc. (ALXO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ALX Oncology Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ALX Oncology Holdings Inc.'s ROE?
How is the ROE calculated for ALX Oncology Holdings Inc. (ALXO)?
What is the highest ROE for ALX Oncology Holdings Inc. (ALXO)?
What is the 3-year average ROE for ALX Oncology Holdings Inc. (ALXO)?
What is the 5-year average ROE for ALX Oncology Holdings Inc. (ALXO)?
How does the current ROE for ALX Oncology Holdings Inc. (ALXO) compare to its historical average?